Invasión

Spaces Making Up "The Interstitium" Are Connected

Retrieved on: 
Wednesday, March 31, 2021
Branches of biology, Body fluids, Oncology, Cell biology, Extracellular fluid, Interstitial, Invasión, Tissue, Connective tissue

This is the finding of a study published online March 31in Communications Biology, an open access journal of Nature.

Key Points: 
  • This is the finding of a study published online March 31in Communications Biology, an open access journal of Nature.
  • Observing no gaps in the HA throughout all interstitial spaces, the authors concluded that such spaces are continuous, with open channels running through all connective tissues.
  • However, research in the field has shown that early on, such invasion often proceeds without tissue breakdown by enzymes, and could happen instead through pre-existing spaces.
  • Moving forward, the team is also developing techniques to examine the protein content in interstitial spaces to understand whether or not nearby tumors alter interstitial spaces to enable cancer cell movement through them.

AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Proprietary Compounds and Methods Targeting Tumor Metastasis Through QSOX1

Retrieved on: 
Tuesday, September 22, 2020
Cancer, Oncology, Clinical medicine, Medicine, Cancer pathology, Cancer treatments, Antineoplastic drugs, Invasión, E-selectin, Metástasis, Chemotherapy

15/748,784) on anti-neoplastic compounds and methods targeting Quiescin Sulfhydryl Oxidase 1 (QSOX1), an enzyme important for tumor cell growth, invasion and metastasis.

Key Points: 
  • 15/748,784) on anti-neoplastic compounds and methods targeting Quiescin Sulfhydryl Oxidase 1 (QSOX1), an enzyme important for tumor cell growth, invasion and metastasis.
  • SBI-183 selectively targets QSOX1 and, in animal models, has been found to inhibit tumor growth, invasion and suppress metastasis of tumors by inactivating QSOX1.
  • At our core, we are an oncology company dedicated to reducing metastasis in cancer patients around the world.
  • Currently, SPX-1009 has proven itself to be tenfold more potent in suppressing tumor invasion and metastasis in vitro than SBI-183.

CytoDyn’s CEO Dr. Pourhassan and CMO Dr. Kelly to Appear on DrBeen Webcast Tuesday, September 22, 2020

Retrieved on: 
Monday, September 21, 2020
Medical specialties, PRO 140, Health, Drugs, Breast cancer, CCR5, Triple-negative breast cancer, CCR5 receptor antagonist, Management of HIV/AIDS, Invasión, Cancer, HIV

The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses.

Key Points: 
  • The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses.
  • The first indication is a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer.
  • Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans.
  • In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control.

ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting

Retrieved on: 
Monday, June 22, 2020
Biotechnology, Pharmaceutical, Health, Branches of biology, Cancer, Medical specialties, C-Met, Breast cancer, Cancer research, Oncology, Invasión, Epithelial–mesenchymal transition

The findings were shared via poster presentation at the virtual American Association for Cancer Research (AACR) Annual Meeting II.

Key Points: 
  • The findings were shared via poster presentation at the virtual American Association for Cancer Research (AACR) Annual Meeting II.
  • IMGN151 demonstrated enhanced anti-tumor activity in both in vitro and in vivo preclinical models, with complete regression of human tumor xenograft models induced in those with high, medium, and low levels of FR expression.
  • Based on these data, we look forward to exploring IMGN151 in the clinic in multiple FR-positive epithelial malignancies, including ovarian, endometrial, triple negative breast, and non-small cell lung cancer.
  • IMGN151 activity was characterized against cell lines and xenograft models with a wide range of FR expression and compared to mirvetuximab soravtansine (IMGN853).

Alethia Biotherapeutics Announces Receipt of FDA Authorization to Begin Phase 2 Development for its EMT Inhibitor, AB-16B5

Retrieved on: 
Thursday, May 21, 2020
Branches of biology, Medicine, Medical specialties, Cancer pathology, Oncology, Immune system, Tyrosine kinase receptors, Cancer treatments, Invasión, Metástasis, C-Met, Immune checkpoint

We are extremely pleased to have achieved this important milestone in the development of AB-16B5 and to continue to advance the clinical development of this promising antibody commented Yves Cornellier, President and CEO of Alethia.

Key Points: 
  • We are extremely pleased to have achieved this important milestone in the development of AB-16B5 and to continue to advance the clinical development of this promising antibody commented Yves Cornellier, President and CEO of Alethia.
  • EMT is a central enabler for solid tumor progression because it triggers metastatic invasion, resistance to several classes of anti-cancer drugs and contributes to immune evasion.
  • There is also increasing evidence that EMT contributes to resistance to immune checkpoint inhibitors.
  • Tumor-associated secreted clusterin is induced early in the EMT cascade and its inhibition with AB-16B5 stops and reverts EMT in animal models.

Circular RNA Limits Skin Cancer Spread

Retrieved on: 
Monday, January 13, 2020
Cancer, RTT, Medicine, Branches of biology, Oncology, Cancer pathology, Melanoma, Metástasis, Skin cancer, Invasión, Nucleic acid, Treatment of cancer

Published online January 13 in Cancer Cell, the new work revolves around circular RNA, a recently described type of ribonucleic acid (RNA).

Key Points: 
  • Published online January 13 in Cancer Cell, the new work revolves around circular RNA, a recently described type of ribonucleic acid (RNA).
  • In patients that die from melanoma, the most lethal form of skin cancer, the aggressive spread, or metastasis, of cancer cells is the primary cause of death.
  • Cancer cells arise from normal cells because of genetic errors, but changes in DNA do not fully explain how the cells spread.
  • When CDR1as was removed using molecular techniques, IGF2BP3 was free to promote cancer cell invasion, which occurs when cells penetrate skin layers and spread to distant organs.

CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis

Retrieved on: 
Wednesday, January 8, 2020
Medicine, Clinical medicine, Cancer pathology, Oncology, Cancer treatments, CXCR4, C-Met, Metástasis, Invasión, Temozolomide, Cancer, CXCR4 antagonist

CXCR4 is a key regulatory receptor involved in tumor growth, invasion, angiogenesis, metastasis, and resistance to therapy.

Key Points: 
  • CXCR4 is a key regulatory receptor involved in tumor growth, invasion, angiogenesis, metastasis, and resistance to therapy.
  • Inhibition of this key regulatory pathway is potentially applicable to a wide range of cancers, as well as orphan indications where CXCR4 signaling is dysregulated.
  • Novel peptide analogs of a mitochondrially encoded peptide (MBT5) demonstrated potent and selective inhibition of human CXCR4 receptor in cell-based assays, with IC50 values in the low nanomolar concentration range.
  • The reduction in tumor growth produced by the combination exceeded the effect of either temozolomide used as a single agent, which reduced tumor growth by 38% compared to control, or the murine checkpoint inhibitor anti-PD-1 antibody, which had no effect on tumor growth in this model.

Moleculin Announces New Data Shows Reversal of Tumor Activity in Animal Models

Retrieved on: 
Thursday, December 19, 2019
Cancer, Medicine, Oncology, Clinical medicine, RTT, Cancer pathology, Metástasis, C-Met, Invasión, Cancer immunotherapy

"Our ongoing sponsored research at MD Anderson has now resulted in new patented discoveries that clearly demonstrate unusually high activity of Annamycin against lung metastatic cancers in animal models.

Key Points: 
  • "Our ongoing sponsored research at MD Anderson has now resulted in new patented discoveries that clearly demonstrate unusually high activity of Annamycin against lung metastatic cancers in animal models.
  • We believe the tumor growth inhibition and even tumor regression observed with Annamycin might offer a new treatment option for patients with lung localized cancers.
  • This notion is also supported by previously observed high activity of Annamycin against multidrug resistant tumors in animal models and its lack of cardiotoxicity thus far supported by both animal studies and clinical studies in humans."
  • We're not just seeing a reduction in tumor growth, but often a reversal of tumor activity resulting in an almost complete reduction of tumor burden."

First Patient in CytoDyn’s Triple-Negative Metastatic Breast Cancer Trial Shows Significant Reduction in Circulating Tumor Cells (CTC) and Reduced Tumor Size

Retrieved on: 
Tuesday, November 12, 2019
Oncology, Medical specialties, Medicine, Branches of biology, CCR5, Circulating tumor cell, Metastatic breast cancer, Metástasis, Epithelial–mesenchymal transition, Invasión

Circulating tumor cells (CTC) in the patients blood decreased significantly after leronlimab therapy at both two-week and five-week time points.

Key Points: 
  • Circulating tumor cells (CTC) in the patients blood decreased significantly after leronlimab therapy at both two-week and five-week time points.
  • Moreover, the reduction of CCR5 expression on EMT cells may prove to be significant, as high CCR5 expression is believed to be crucial for metastases.
  • The treatment of mTNBC with leronlimab in this Phase 1b/2 trial is in addition to metastatic breast cancer (MBC) patients treated with leronlimab under an emergency use IND.
  • Although these are early results in our first patient, we are encouraged by the reduction in both CTC and tumor size.

CytoDyn Sponsored Research Reaffirms the Role of CCR5 in Cancer Biology and Provides a New Potential Cancer Treatment Modality

Retrieved on: 
Friday, August 2, 2019
Medical specialties, Branches of biology, Cancer pathology, Oncology, Medicine, CCR5, RTT, Metástasis, Invasión, Cancer, Host response to cancer therapy

These results together provide the basis for the potential use of leronlimab as a new therapeutic modality for human solid tumors expressing CCR5.

Key Points: 
  • These results together provide the basis for the potential use of leronlimab as a new therapeutic modality for human solid tumors expressing CCR5.
  • "I am honored to have had the opportunity to investigate the role of leronlimab in cancer biology, stated Daniel Lindner, M.D., Ph.D. at the Cleveland Clinic.
  • "Our research provides ground-breaking insight into basic cancer biology, immune involvement in cancer suppression and has identified a potential new therapeutic modality to influencecancer patients' survival."
  • In the setting of cancer, research has shown that CCR5 plays an important role in tumor invasion and metastasis.